Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: A review of their pharmacology, acute toxicity, and metabolism

Forensic Toxicology

Volumn 32, Issue 1, 2014, Pages 1-8

  Zaitsu, Kei ^a   Katagi, Munehiro ^b   Tsuchihashi, Hitoshi ^c   Ishii, Akira ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Chuo ward   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

PVP; Pyrrolidinophenone derivatives; Cathinones; Metabolism; Pharmacology; Toxicity

Indexed keywords

EID: 84895120226     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-013-0218-1     Document Type: Review

References (62)

1. Kalix P (1992) Cathinone, a natural amphetamine. Pharmacol Toxicol 70:77-86
2. Zaitsu K, Katagi M, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2011) Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol 29:73-84
3. Kelly JP (2011) Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 3:439-453
4. Zawilska JB, Wojcieszak J (2013) Designer cathinones - an emerging class of novel recreational drugs. Forensic Sci Int 231:42-53
5. Ammann D, McLaren JM, Gerostamoulos D, Beyer J (2012) Detection and quantification of new designer drugs in human blood: part 2 - designer cathinones. J Anal Toxicol 36:381-389
6. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 31:44-53
7. Chung H, Choi H, Heo S, Kim E, Lee J (2013) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol. doi: 10.1007/s11419-013-0213-6
8. Westphal F, Junge T, Klein B, Fritschi G, Girreser U (2011) Spectroscopic characterization of 3,4-methylenedioxypyrrolidinobutyrophenone: a new designer drug with α-pyrrolidinophenone structure. Forensic Sci Int 209:126-132
9. Brandt SD, Sumnall HR, Measham F, Cole J (2010) Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2:377-382
10. De Paoli G, Maskell PD, Pounder DJ (2011) Naphyrone: analytical profile of the new "legal high" substitute for mephedrone. J Forensic Legal Med 18:93
11. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223-240
12. Nencini P, Ahmed AM (1989) Khat consumption: a pharmacological review. Drug Alcohol Depend 23:19-29
13. Hollister LE, Gillespie HK (1970) A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers. J Clin Pharmacol J New Drugs 10:103-109
14. Gardos G, Cole JO (1971) Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp 13:631-635
15. Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur J Pharmacol 381:63-69
16. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949-1958
17. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192-1203
18. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470
19. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4- methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38:552-562
20. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167:407-420
21. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22:231-236
22. Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12-15
23. Dargan PI, Sedefov R, Gallegos A, Wood DM (2011) The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 3:454-463
24. Gustavsson D, Escher C (2009) Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. (in Swedish and English abstract). Lakartidningen 106:2769-2771
25. Wood DM, Greene SL, Dargan PI (2011) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28:280-282
26. Borek HA, Holstege CP (2012) Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 60:103-105
27. Ross EA, Watson M, Goldberger B (2011) "Bath salts" intoxication. N Engl J Med 365:967-968
28. Murray B, Murphy C, Beuhler M (2012) Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69-75
29. Albers DS, Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114
30. Hall AP, Henry JA (2006) Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 96:678-685
31. Baumann MH, Rothman RB (2009) Chapter 10 - Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). In: Hari Shanker S (ed) International review of neurobiology, vol. 88. Academic Press, New York, pp 257-296
32. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71:130-140
33. Mugele J, Nañagas KA, Tormoehlen LM (2012) Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 60:100-102
34. Adebamiro A, Perazella MA (2012) Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis 59:273-275
35. Sauer C, Hoffmann K, Schimmel U, Peters FT (2011) Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha- pyrrolidinohexanophenone (MPHP). Forensic Sci Int 208:e20-e25
36. Saito T, Namera A, Osawa M, Aoki H, Inokuchi S (2013) SPME-GC-MS analysis of α-pyrrolidinovaleorophenone in blood in a fatal poisoning case. Forensic Toxicol 31:328-332
37. Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (2013) Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol 51:899-903
38. Michaelis W, Russel JH, Schindler O (1970) Metabolism of pyrovalerone hydrochloride. J Med Chem 13:497-503
39. Shin H-S, Shin Y-SO, Lee S, Park B-B (1996) Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 20:568-572
40. Lho D-S, Lee J, Kim S, Park J, Shin H-S (1996) Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection. J Chromatogr B 687:253-259
41. Springer D, Peters FT, Fritschi G, Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B 773:25-33
42. Springer D, Peters FT, Fritschi G, Maurer HH (2003) New designer drug 4′-methyl-α-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B 789:79-91
43. Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 796:253-266
44. Springer D, Fritschi G, Maurer HH (2003) Metabolism and toxicological detection of the new designer drug 4′-methoxy-α- pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 793:331-342
45. Springer D, Fritschi G, Maurer HH (2003) Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α- pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B 793:377-388
46. Peters FT, Meyer MR, Fritschi G, Maurer HH (2005) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 824:81-91
47. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952-964
48. Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Comm Mass Spectrom 24:2706-2714
49. Meyer MR, Du P, Schuster F, Maurer HH (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45:1426-1442
50. Tyrkkö E, Pelander A, Ketola R, Ojanperä I (2013) In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal Bioanal Chem 405:6697-6709
51. Namera A, Konuma K, Kawamura M, Saito T, Nakamoto A, Yahata M, Ohta S, Miyazaki S, Shiraishi H, Nagao M (2013) Time-course profile of urinary excretion of intravenously administered α-pyrrolidinovalerophenone and α-pyrrolidinobutiophenone in a human. Forensic Toxicol. doi: 10.1007/s11419-013-0203-8
52. Shima N, Katagi M, Kamata H, Matsuta S, Sasaki K, Kamata T, Nishioka H, Miki A, Tatsuno M, Zaitsu K, Ishii A, Sato T, Tsuchihashi H, Suzuki K (2013) Metabolism of the newly encountered designer drug α- pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol. doi: 10.1007/s11419-013-0202-9
53. Beckett AH, Midha KK (1974) The identification of four metabolic products after incubation of p-methoxyamphetamine with liver preparations of various species. Xenobiotica 4:297-311
54. Hubbard JW, Midha KK, Cooper JK (1977) The metabolism of p-methoxyamphetamine in dog and monkey. O-Demethylation as a major route. Drug Metab Dispos 5:329-334
55. Kitchen I, Tremblay J, André J, Dring LG, Idle JR, Smith RL, Williams RT (1979) Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9:397-404
56. Staack RF, Fehn J, Maurer HH (2003) New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B 789:27-41
57. Staack RF, Maurer HH (2005) Metabolism of designer drugs of abuse. Curr Drug Metab 6:259-274
58. Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, Hayashi T, Kuroki H, Matoba R (2008) Determination of a newly encountered designer drug "p-methoxyethylamphetamine" and its metabolites in human urine and blood. Forensic Sci Int 177:77-84
59. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de la Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208
60. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H (2006) Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36:709-723
61. Shima N, Katagi M, Kamata H, Zaitsu K, Kamata T, Nishikawa M, Miki A, Tsuchihashi H, Sakuma T, Nemoto N (2008) Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica 38:314-324
62. Zaitsu K, Katagi M, Kamata HT, Kamata T, Shima N, Miki A, Tsuchihashi H, Mori Y (2009) Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188:131-139